Artiva Biotherapeutics, Inc. (ARTV) AI Stock Analysis

• Market Cap: $136.44M
• Dividend Yield: N/A
• Average Volume (3M): 166.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: -100.00%
• EPS Growth: -17.10%
• Country: US
• Employees: 96
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 24,716,673
• 10 Day Avg. Volume: 225,904
• 30 Day Avg. Volume: 166,722
• PEG Ratio: 0.04
• Price to Book (P/B): 0.95
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.32
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -89.60
• Enterprise Value/Ebitda: -1.38
• 1Y Price Target: $17.00
• Price Target Upside: 207.97% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -3.39
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $5.50 ▼(-0.36% Downside)
• Action: Reiterated Date: 03/11/26
• Date: Action: Reiterated 03/11/26

The score is held down primarily by weak financial performance—minimal revenue, widening losses, and persistent cash burn—despite modest leverage. Technicals are a key positive with a clear uptrend, though momentum appears overextended. Valuation signals are constrained by negative earnings and no dividend data, while recent executive/board additions provide a modest positive offset.

Positive Factors

Modest leverage / balance sheet flexibility

Low absolute debt and a debt-to-equity near 0.10 provide structural financing flexibility for an R&D-intensive biotech. This reduces near-term insolvency risk, supports continued pipeline funding and strategic optionality (partnerships or M&A) without immediate refinancing pressure.

Experienced CFO appointment

Bringing in a long-tenured pharma/biotech finance executive strengthens governance and capital strategy. His experience at large biotech/pharma can improve budgeting, capital markets access and transaction execution, aligning financial discipline with long-term pipeline development.

Board commercial expertise

Adding a senior commercial executive to the board enhances commercialization planning and go-to-market capability. Structural commercial expertise improves launch readiness, partner selection and pricing strategy, increasing the odds of successful revenue scaling when products reach market.

Negative Factors

High and accelerating cash burn

Consistent negative operating and free cash flow, with a marked increase in 2025, creates structural dependency on external funding. Persistent burn constrains strategic optionality, raises dilution risk, and forces trade-offs between advancing the pipeline and preserving runway absent durable revenue.

Pre-commercial status and widening losses

The company remains pre-commercial with volatile, minimal revenue and materially wider annual losses. This structural lack of recurring revenue and growing losses mean long-term value hinges on successful clinical and regulatory outcomes, elevating execution and clinical risk.

Historical equity instability and negative ROE

Past negative equity and persistently negative ROE reflect prior dilution and unprofitable operations. This pattern signals ongoing financing vulnerability: future capital raises may be required, increasing dilution risk and complicating sustainable shareholder return creation over the medium term.

Artiva Biotherapeutics, Inc. Business Overview & Revenue Model

Company Description

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

How the Company Makes Money

null

Artiva Biotherapeutics, Inc. Financial Statement Overview

Summary

Income and cash flow are the primary constraints: the company is pre-commercial with revenue falling to near-zero and losses widening materially, alongside persistent negative operating/free cash flow and an accelerating 2025 burn. The balance sheet is a partial offset with modest leverage, but historically unstable equity and ongoing losses point to continued financing/dilution risk.

Income Statement

The company remains pre-commercial with minimal and volatile revenue (down from $33.5M in 2023 to near-zero in 2025), while losses have widened materially (net loss roughly -$27.7M in 2023 vs. about -$83.9M in 2025). Profitability is consistently negative and trending worse in the most recent year, indicating a higher ongoing burn profile and limited near-term earnings visibility.

Balance Sheet

Leverage is modest, with debt relatively low versus equity in the latest period (debt-to-equity around 0.10 in 2025 and ~0.08 in 2024), which provides financing flexibility for an R&D-heavy biotech. However, equity has been unstable historically (negative in 2020–2023 before turning positive in 2024–2025), and returns on equity are negative in the latest periods due to continued losses—highlighting dilution/financing risk if cash burn persists.

Cash Flow

Cash generation is weak: operating cash flow and free cash flow are negative every year shown, and the cash burn accelerated in 2025 (operating cash flow about -$76.8M; free cash flow about -$79.3M). There is a positive year-over-year improvement in free cash flow growth in 2025, but absolute cash outflows remain large and recurring, implying ongoing reliance on external capital until revenues scale.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	251.00K	33.49M	4.93M	2.00M
Gross Profit	-2.60M	251.00K	33.49M	4.93M	2.00M
EBITDA	-88.01M	-64.85M	-28.41M	-58.67M	-71.58M
Net Income	-83.86M	-58.49M	-27.70M	-58.39M	-71.83M
Balance Sheet
Total Assets	130.94M	209.58M	105.11M	133.05M	169.93M
Cash, Cash Equivalents and Short-Term Investments	108.01M	185.43M	76.97M	102.53M	160.92M
Total Debt	10.94M	14.35M	16.91M	19.45M	1.74M
Total Liabilities	20.97M	22.94M	267.13M	273.75M	258.78M
Stockholders Equity	109.97M	186.64M	-162.01M	-140.70M	-88.86M
Cash Flow
Free Cash Flow	-79.34M	-55.67M	-50.69M	-57.13M	-17.03M
Operating Cash Flow	-76.75M	-55.03M	-47.43M	-50.83M	-15.30M
Investing Cash Flow	63.41M	-120.46M	-25.98M	-6.30M	-1.72M
Financing Cash Flow	9.00K	162.23M	24.39M	-1.26M	152.75M

Artiva Biotherapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTV, the sentiment is Neutral. The current price of 5.52 is below the 20-day moving average (MA) of 5.73, above the 50-day MA of 4.91, and above the 200-day MA of 3.53, indicating a neutral trend. The MACD of 0.39 indicates Positive momentum. The RSI at 50.25 is Neutral, neither overbought nor oversold. The STOCH value of 21.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARTV.

Artiva Biotherapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARTV	52 Neutral	$136.44M	-1.25	-60.22%	―	-100.00%	-17.10%
JSPR	52 Neutral	$34.14M	-0.53	-191.12%	―	―	-24.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PLRX	49 Neutral	$82.35M	-0.79	-69.56%	―	―	14.19%
ACET	45 Neutral	$67.85M	-0.50	-77.90%	―	―	25.89%
ABVC	41 Neutral	$32.82M	-6.26	-88.89%	―	56.52%	75.22%

Artiva Biotherapeutics, Inc. Corporate Events

Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer

Artiva Biotherapeutics announced on February 24, 2026 that its board appointed veteran finance executive Thad Huston as chief financial officer, effective February 18, 2026, making him the company’s principal financial and accounting officer. Huston brings more than three decades of global leadership across pharmaceuticals, biotechnology and medical devices, including senior roles at Galapagos NV, Kite Pharma, LivaNova and Johnson & Johnson, which is expected to bolster Artiva’s financial strategy and operational discipline as it advances its therapeutic pipeline.

Under an employment agreement, Huston will receive a $540,000 annual base salary, a target annual bonus equal to 40% of base pay for 2026, and an inducement grant of 220,000 restricted stock units that vest over four years, aligning his compensation with long-term shareholder value. The agreement also provides tiered severance and accelerated equity vesting benefits in the event of certain terminations, including in connection with a change of control, signaling Artiva’s intent to secure stable senior financial leadership during potential strategic transactions and future growth phases.

The most recent analyst rating on (ARTV) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Artiva Biotherapeutics, Inc. stock, see the ARTV Stock Forecast page.

Artiva Biotherapeutics Adds Veteran Executive Elaine Sorg to Board

On February 18, 2026, Artiva Biotherapeutics appointed veteran pharmaceutical executive Elaine Sorg as a Class I director, with her term running until the company’s 2028 annual shareholder meeting. The decision followed a recommendation from the Nominating and Corporate Governance Committee, and the company noted there were no related-party arrangements or disclosable transactions tied to her selection.

Sorg brings more than 35 years of senior leadership experience at major pharmaceutical groups including AbbVie and Eli Lilly, where she last served as Senior Vice President and President of AbbVie’s U.S. commercial operations until January 2024. Her appointment strengthens Artiva’s board with deep U.S. commercial and global healthcare expertise and is accompanied by standard non-employee director compensation, including an annual cash retainer and time-vested stock options that align her incentives with long-term shareholder interests.

The most recent analyst rating on (ARTV) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Artiva Biotherapeutics, Inc. stock, see the ARTV Stock Forecast page.